IMS Health is an international company that supplies the pharmaceutical industry with sales data and consulting services. IMS Health was founded in 1954 by Bill Froch and David Dubow. Today IMS has operations in more than 100 countries, a global workforce of 7,600+ employees, and revenues of $2 billion. It recently moved its headquarters from Fairfield, CT to Norwalk, CT.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2010 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of IMS Health
Names of Lobbyists
Most Frequently Disclosed Lobbying Issues
- Health Issues
RegulationsMentioned in 58 dockets; Submitted to 3 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "IMS Health" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for IMS Health
- Toggle 1 HHS Office of the National Coordinator for Health Information Technology; Health Information Technology; Request for Information Regarding the President’s Council of Advisors on Science and Technology (PCAST) Report Entitled ‘‘Realizing the Full Potential of Health Information Technology To Improve Healthcare for Americans: The Path Forward 2010
- Toggle 1 HHS Meaningful use of Healthcare Information Technology 2009
- Toggle 1 HHS Modifications to the HIPAA Privacy, Security, and Enforcement Rules Under the Health Information Technology for Economic and Clinical Health Act; Proposed Rule 2010
Mentions in Document Text
View all mentions data for IMS Health
- Toggle 6 FDA Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting 2009
- Toggle 6 FDA Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner 2009
- Toggle 5 FDA Availability of Information Related to the Sentinel Initiative 2009
- Toggle 4 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 4 USTR 2010 Special 301 2010
- Toggle 4 FDA Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting. 2009
- Toggle 4 CMS Medicare Part D Data 2010
- Toggle 3 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 2010
- Toggle 3 EPA Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2010 2009
- Toggle 2 FDA Determine Whether Oxycotin 10mgs, 15 mgs, 20mgs, 30mgs, 40mgs, 60mgs, 80mgs, and 160mgs, Oxycotin Hydrochloride Extended-Release Tablets has Been Voluntarily Withdrawn or Withheld From Sale for Safety or Efficacy Reasons 2010